GlassScriptPhysician profile
Michael William Shaw Moore
NPI 1508151481
$5,723.79
in general payments reported to CMS, 2019-2025
21 companies · $837 in 2025
The $837 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $412 · 2021: $694 · 2022: $479 · 2023: $1,056 · 2024: $1,281 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833 · Travel and Lodging: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.50 |
| Travel and Lodging | $341.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,563.64 | 2023-2025 | Inspire |
| Acclarent, INC | $1,039.78 | 2019-2023 | Acclarent Aera |
| Stryker Corporation | $510.66 | 2019-2022 | |
| Intersect Ent, INC. | $365.19 | 2021 | |
| Glaxosmithkline, LLC. | $348.34 | 2022-2025 | Nucala |
| Integra Lifesciences Corporation | $310.31 | 2024-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Aerin Medical INC. | $282.64 | 2019-2024 | |
| Optinose US, INC. | $219.75 | 2019-2020 | |
| Medtronic, INC. | $218.18 | 2022-2024 | Propel, Sinuva, Nuvent |
| Genzyme Corporation | $150.29 | 2023-2025 | |
| Hologic Sales and Service, LLC | $148.38 | 2024 | Coolseal Generator |
| Medtronic USA, INC. | $118.53 | 2019 | |
| Olympus America INC. | $115.67 | 2019-2024 | Olympus, Olympus |
| Novartis Pharmaceuticals Corporation | $96.20 | 2019-2023 | |
| Neurent Medical Limited | $78.79 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $67.07 | 2023-2024 | Dupixent |
| Ensodata, INC. | $23.43 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $20.76 | 2024 | Exparel |
| Regeneron Pharmaceuticals, INC. | $20.01 | 2024 | Dupixent |
| Hikma Pharmaceuticals USA | $17.39 | 2023 | Ryaltris |
| 3b Medical, INC. | $8.78 | 2024 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.